Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $15.10 and traded as low as $13.33. MediWound shares last traded at $13.65, with a volume of 73,110 shares trading hands.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on MDWD shares. Wall Street Zen cut shares of MediWound from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Weiss Ratings lowered MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, September 8th. Oppenheimer restated an "outperform" rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of MediWound in a research note on Wednesday, September 16th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $33.00.
Get Our Latest Report on MDWD
MediWound Stock Down 2.2%
The firm has a market capitalization of $175.40 million, a PE ratio of -7.58 and a beta of 0.14. The firm's 50 day moving average price is $13.69 and its two-hundred day moving average price is $15.10.
MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million for the quarter, compared to analysts' expectations of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. On average, sell-side analysts anticipate that MediWound Ltd. will post -2.31 earnings per share for the current fiscal year.
Insider Activity
In related news, COO Shmuel Hess sold 3,958 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 9.20% of the company's stock.
Institutional Investors Weigh In On MediWound
Hedge funds have recently bought and sold shares of the business. Clal Insurance Enterprises Holdings Ltd raised its position in shares of MediWound by 22.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 71,000 shares of the biopharmaceutical company's stock valued at $1,311,000 after purchasing an additional 13,196 shares in the last quarter. UBS Group AG grew its position in shares of MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company's stock worth $2,678,000 after buying an additional 68,756 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC grew its position in shares of MediWound by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company's stock worth $3,222,000 after buying an additional 16,081 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company's stock.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company's products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.
MediWound's lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
